| Pharmaceutical Information |
| Drug Name |
Pinaverium bromide |
| Drug ID |
BADD_D01775 |
| Description |
Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS) [A19702]. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. |
| Indications and Usage |
Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract. |
| Marketing Status |
approved |
| ATC Code |
A03AX04 |
| DrugBank ID |
DB09090
|
| KEGG ID |
D07094
|
| MeSH ID |
C013199
|
| PubChem ID |
40703
|
| TTD Drug ID |
D0J1NQ
|
| NDC Product Code |
65372-1135; 52128-175 |
| UNII |
7SCF54H12J
|
| Synonyms |
pinaverium | Dicetel | pinaverium bromide | 4-(6-bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium bromide | Eldicet |
|
| Chemical Information |
| Molecular Formula |
C26H41Br2NO4 |
| CAS Registry Number |
53251-94-8 |
| SMILES |
CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.[Br-] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
